New long acting dopamine treatments can dramatically extend good on time for people living with Parkinson's

Maximising the time when medication works effectively and minimising the periods when symptoms return is the central focus of managing Parkinson's today. For individuals living with the condition, daily life is often defined by the balance between good working periods and the sudden, disruptive return of movement difficulties. Finding ways to extend the beneficial window and reduce the unpredictable return of symptoms remains the primary goal of modern treatment. Remarkably, the foundation of this strategy relies on a chemical method first introduced in the 1960s, which remains the single most effective core tool available today. The persistent reliance on standard dopamine therapy The primary challenge in managing Parkinson's stems from how the body processes levodopa, which has been the gold standard treatment since its introduction in the late 1960s. Levodopa converts into dopamine in the brain to facilitate smooth, controlled movement. However, the chemical has an incredibly short lifespan in the bloodstream, lasting only about 60 to 90 minutes on its own. Even when mixed with a companion chemical called carbidopa to help it last longer, the combination typically works for only three to four hours per dose. This brief window creates predictable movement fluctuations. The beneficial periods are known as on time, whilst the intervals where the benefits of the medication rapidly vanish are known as off time. During off periods, individuals face a sudden return of stiffness, tremors, and anxiety. Statistics from the Michael J. Fox Foundation reveal the widespread nature of this issue, noting that about 70% of individuals experience at least two off periods every single day. Furthermore, roughly 52% endure one to three hours of off time daily, and around 25% face three to six hours of poorly controlled symptoms each day. Despite the known effectiveness of advanced device aided therapies to smooth out these bumps, actual uptake remains remarkably low. A study from the Icahn School of Medicine at Mount Sinai found that whilst 22% of Medicare beneficiaries had advanced Parkinson's, only 2% actually received device assisted treatments. The long term realities of deep brain stimulation For several decades, technological treatments like deep brain stimulation have attracted considerable attention in research circles as an alternative to frequent dosing. However, a comprehensive ten year study conducted by the Veterans Affairs healthcare system and the University of California San Francisco has highlighted the long term boundaries of this surgical approach, sparking a renewed focus on innovative pharmaceutical options to address the persistent challenge of chemical wearing off. The long term study followed 156 veterans with advanced Parkinson's over a decade to compare two different surgical placement sites in the brain for deep brain stimulation. The results confirmed that whilst the treatment significantly improves specific movement symptoms such as tremors, stiffness, and involuntary wiggly movements, it has a much smaller effect on other issues like slow movement and balance difficulties. Crucially, the study showed that deep brain stimulation does not halt the overall progression of Parkinson's. Over seven to ten years, individuals in the study still experienced a decline in quality of life, greater daily disability, and worsening thinking and memory skills. Whilst recent technological updates like directional electrodes and adaptive programming may reduce side effects in the future, the natural progression of the condition highlights a critical need for alternative chemical approaches. A trio of new pharmaceutical arrivals To combat these gaps in care, the medical pipeline has produced three major drug approvals designed to keep chemical levels steady, extend on time, and minimize daily off time. The first of these is Crexont, approved in August 2024. This advanced capsule combines immediate release and extended release forms of carbidopa and levodopa. It uses a specialized sticky polymer that optimises how the gut absorbs the medicine, providing the longest lasting blood levels of any current oral option. The other two advancements move away from oral tablets entirely, relying on continuous delivery systems. Vyalev utilizes a continuous pump to deliver a steady supply of carbidopa and levodopa directly under the skin, avoiding the unpredictable absorption issues of the stomach. Similarly, Onapgo is a separate continuous skin infusion pump that provides a steady, constant stream of apomorphine, which mimics the action of dopamine in the brain. Real world success and strict medical guidelines The Veterans Affairs system added Crexont to its official medicine list in early 2025. Because the system treats roughly 10% of all individuals with Parkinson's in the United States, it has established specific guidelines for who can access the drug. To qualify, individuals must be under the care of a specialist neurologist, have a formal diagnosis of Parkinson's or specific toxin induced movement issues, and experience wearing off symptoms at intervals of four hours or less despite already taking a mix of standard controlled release and immediate release tablets. Furthermore, guidelines state that individuals must not have used nonselective monoamine oxidase inhibitors within the past fortnight, and they must have shown an inadequate response or intolerance to at least two other classes of Parkinson's medications, such as dopamine agonists or enzyme blockers. Recent real world data highlights the practical impact of these newer capsule formulations. Early six week results from an ongoing multi centre trial called ELEVATE-PD evaluated 55 individuals with a mean age of 66.4 who switched to Crexont from older regimens. The clinical improvements across different previous medication groups demonstrate significant gains in daily symptom control. For individuals previously taking standard immediate release levodopa, switching to the newer capsule provided an extra 3.13 hours of good on time daily and reduced daily off time by 2.83 hours, resulting in an overall movement score improvement of 14.2 points. Those who had been taking immediate release levodopa alongside an enzyme blocker saw an extra 2.31 hours of daily on time, a reduction in off time of 2.36 hours, and a 4.1 point improvement in overall movement scores. For individuals switching from older extended release capsules, known as Rytary, the new formulation provided 1.80 hours of extra daily on time, reduced off time by 2.57 hours, and improved overall movement scores by 13.9 points. The trial, which aims to follow 220 participants over 13 to 14 months across ten clinical visits, also showed that the medicine increased the amount of good working time achieved from every single individual dose. Side effects during the switch were generally mild to moderate and matched what is typically seen with standard dopamine therapies. These findings build upon the earlier Phase 3 RISE-PD clinical trial, which proved that the advanced capsules provide a more sustained benefit throughout the day even when taken only three times a day, compared to standard immediate release versions taken five times a day. Global availability and regulatory status of Crexont Whilst Crexont has become widely accessible through pharmacies across the United States following its commercial rollout, its availability in other major regions remains in a transitional phase. In the United Kingdom and Europe, the medication has been submitted for formal regulatory approval to the European Medicines Agency. To support this transition into European clinical practice, a dedicated Phase 3b clinical trial called ADIP was launched across several countries, including Italy, Poland, and Spain, to evaluate its effectiveness in routine European care settings. An exclusive partnership is currently in place to manage the commercial distribution and approvals specifically for the United Kingdom, Switzerland, and the European Union once regulatory clearance is officially granted. In Australia and other international territories, patients generally experience a longer waiting window for direct local access following a US release. However, until standard regional licensing through the Therapeutic Goods Administration and local healthcare funding are finalized, specialist neurologists in these parts of the world can sometimes explore individual compassionate use or specific named patient import regulations to access the capsules earlier for those who meet the clinical criteria. The double edged sword of continuous infusion pumps Whilst continuous infusion pumps like Vyalev and Onapgo offer a highly effective way to bypass the stomach and provide steady relief, recent real world evidence reveals a significant obstacle in how long people actually stay on these treatments. A new multi centre study published in May 2026 in the Journal of Neurology tracked 108 people using continuous subcutaneous infusion over a six month period to see how they managed in routine care. The research showed that the continuous infusion brought clear benefits, particularly in reducing involuntary movements, improving daily living experiences, and easing bodily discomfort. However, the study uncovered a very high drop off rate among users. Within just six months, nearly 40% of the individuals discontinued the continuous infusion treatment, with most of them stopping within the first 90 days. The main drivers behind this high discontinuation rate were insufficient efficacy and adverse events. Interestingly, the researchers found that a longer duration of living with Parkinson's was strongly linked to a higher likelihood of stopping the pump. Difficulties related to emotional well being, social support, cognition, and the social stigma sometimes felt when using a visible medical device also played a major role in whether someone stayed on the therapy. This highlights that whilst continuous infusions are a powerful tool for extending on time, the practical and physical demands of managing a pump mean they may not be a long term solution for everyone.